TWMP
ANIP icon

Taylor Wealth Management Partners’s ANI Pharmaceuticals ANIP Stock Holding History

Taylor Wealth Management Partners’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-10
Closed – – 160
2017
Q1 		$0 Hold
10
– – ﹤0.01% 159
2016
Q4 		$1K Buy
+10
New +$611 ﹤0.01% 158

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Taylor Wealth Management Partners's ANIP Position: Q2 2017 in Review

Taylor Wealth Management Partners sold out of ANI Pharmaceuticals (ANIP) in Q2 2017, closing a stake of 10 shares.

Taylor Wealth Management Partners first reported a position in ANIP in Q4 2016 and held it in 2 quarters. The position peaked at $1K in Q4 2016. 151 funds tracked by Wall St. Rank hold ANIP as of Q2 2017.

  • Taylor Wealth Management Partners reported no remaining ANI Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Taylor Wealth Management Partners sold 10 ANI Pharmaceuticals shares in Q2 2017.
  • Taylor Wealth Management Partners first reported a position in ANI Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Taylor Wealth Management Partners's ANI Pharmaceuticals position peaked at $1K in Q4 2016.
  • 151 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2017.

Based on Taylor Wealth Management Partners's 13F filing for Q2 2017, filed 21 Jul 2017.